Beurteilung des Kontrastsehens von Patienten mit idiopathischem Makulaforamen bzw. vitreomakulärer Traktion 6 Monate nach Injektion von Ocriplasmin
Investigation of the contrast vision of patients with idiopathic macula foramina or vitreomacular traction treated with Ocriplasmin up to six months after injection
von Nikolas Schrader
Datum der mündl. Prüfung:2020-11-12
Erschienen:2020-11-03
Betreuer:Prof. Dr. Nicolas Feltgen
Gutachter:Prof. Dr. Rainer Laskawi
Gutachter:Prof. Dr. Thomas Meyer
Dateien
Name:Beurteilung des Kontrastsehens von Patienten...pdf
Size:3.27Mb
Format:PDF
Zusammenfassung
Englisch
BACKGROUND: Ocriplasmin is admitted for treatment of vitreomacular traction and small macular foramina respectively. Anatomic changes are often accompanied by improvement in function. We were interested in whether or not the injection of Ocriplasmin had an effect on contrast vision. METHODS: We recruited 20 patients (16 female, four male; eleven patients with vitreomacular traction and nine patients treated with macula foramina). The examinations were conducted preoperative on the day of surgery; one week, four weeks and six months after injection. We investigated the best corrected visual acuity (BCVA), OCT-findings, contrast vision by Bailey-Lovie-Chart and Freiburg-Visual-Acuity-&-Contrast-Test (FrACT) within a subgroup of eight patients. One patient had to be excluded from analysis just before injection. RESULTS: 13 of the 19 recruited patients (68,4 %) showed a resolution of the tractive connections between retina and vitreous body in the OCT, three had a persistent traction and five patients (three with macula foramina) had to undergo a secondary vitrectomy. We observed a significant improvement in mean visual acuity from 0.36 logMAR preoperative to 0.28 logMAR after four weeks and 0.17 logMAR at the end of our survey. Three of the 19 patients showed temporary reduced contrast vision in the Bailey-Lovie-Chart. In the examination by FrACT we noticed an improvement of contrast vision after one week (logCSWeber 1.40) and at the end of our survey (logCSWeber 1.51) compared to the initial examination (logCSWeber 1.10). CONCLUSION: We observed an improvement in visual acuity and in contrast vision after injection of Ocriplasmin in our study. Because of a large systemic scatter of our measurements, this outcome may only be interpreted as missing reduction in contrast vision after injection of Ocriplasmin.
Keywords: ocriplasmin, contrast vision, Freiburg-Visual-Acuity-&-Contrast-Test, Bailey-Lovie-Chart